文献速递术前评估与围术期医学疼痛医学

门诊手术术后恶心呕吐预防中氟哌利多与昂丹司琼相关静坐不能的发生率:多中心随机对照试验

Incidence of akathisia after postoperative nausea and vomiting prophylaxis with droperidol and ondansetron in outpatient surgery: A multicentre controlled randomised trial.
PubMed 文献 · Eur J Anaesthesiol · 2018-01-01

这项多中心随机双盲对照试验纳入297例门诊全麻手术患者,比较氟哌利多0.625 mg、1.25 mg与昂丹司琼4 mg(均联合地塞米松4 mg)预防术后恶心呕吐(PONV)时静坐不能的发生率。结果显示三组静坐不能发生率分别为1.2%、3.4%和0.8%,组间差异无统计学意义(P=0.52),总体发生率较低。

要点

  • 门诊全麻手术使用氟哌利多或昂丹司琼预防PONV时静坐不能发生率低(0.8%至3.4%)。
  • 氟哌利多0.625 mg、1.25 mg与昂丹司琼4 mg三组间静坐不能发生率差异无统计学意义(P=0.52)。
  • 两剂氟哌利多之间静坐不能发生率未显示显著差异。

核心结论

  • 门诊全麻手术使用氟哌利多或昂丹司琼预防PONV与较低的静坐不能发生率(0.8%至3.4%)相关。

研究设计与样本

  • 随机对照双盲试验,2014年1月至9月在两家大学医院中心和两家私人诊所进行,纳入297例门诊全麻手术患者。
  • 患者随机接受氟哌利多0.625 mg、氟哌利多1.25 mg或昂丹司琼4 mg,三组均另接受地塞米松4 mg。

主要发现

  • 昂丹司琼组静坐不能发生1/118(0.8%),氟哌利多0.625 mg组1/84(1.2%),氟哌利多1.25 mg组3/87(3.4%)。
  • 三组间静坐不能发生率差异无统计学意义(P = 0.52)。
  • 两剂氟哌利多之间静坐不能发生率未显示显著差异。
  • 唯一一例明显静坐不能并接受苯二氮䓬类药物治疗的病例出现在氟哌利多1.25 mg组。

关键数值与推荐

  • 静坐不能评估采用Barnes静坐不能评定量表的全球临床评估分项,于术后4小时在麻醉后监护室离室后评估。
  • 排除标准包括氟哌利多和昂丹司琼禁忌、使用精神药物或苯二氮䓬类药物、或精神病病史。

临床怎么用

  • 门诊全麻手术中采用氟哌利多0.625 mg或1.25 mg或昂丹司琼4 mg预防PONV时,静坐不能总体发生率低。
  • 氟哌利多1.25 mg组观察到唯一一例需苯二氮䓬类治疗的明显静坐不能,临床仍需保持警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Akathisia, a distressing movement disorder induced by butyrophenones, has been described with low doses of droperidol used for postoperative nausea and vomiting (PONV) prophylaxis, but the incidence remains unclear. OBJECTIVES: To determine the incidence of akathisia after PONV prophylaxis with two doses of droperidol in comparison with ondansetron, in patients undergoing ambulatory surgery. We hypothesised that the incidence of akathisia is higher with droperidol than that with ondansetron. DESIGN: Randomised controlled double blind trial. SETTING: Two University Hospital Centres and two private Clinics from January to September 2014. PATIENTS: Patients (n=297) undergoing general anaesthesia for ambulatory surgery were randomly allocated to receive PONV prophylaxis with droperidol (0.625 or 1.25 mg) or ondansetron 4 mg; patients of the three groups also received 4 mg of dexamethasone. Exclusion criteria were contraindication to droperidol and ondansetron, use of psychotropic medications or benzodiazepines or history of psychotic illness. INTERVENTIONS: Participants received droperidol (0.625 or 1.25 mg) or ondansetron 4 mg during general anaesthesia. After discharge from the postanaesthesia care unit presence and severity of akathisia were assessed using the Barnes Akathisia Rating Scale at 4 h postoperatively. MAIN OUTCOME MEASURES: Score of the Global Clinical Assessment of Akathisia of Barnes Akathisia Rating Scale. RESULTS: The number of akathisia observed was 1/118 (0.8%) in the ondansetron group, 1/84 (1.2%) in droperidol 0.625 mg group, and 3/87 (3.4%) in droperidol 1.25 mg group. The akathisia rate difference among the three groups was not significant (P = 0.52). We could not demonstrate significant differences in the incidence of akathisia between the two doses of droperidol. The only case of marked akathisia treated with benzodiazepines was observed after droperidol 1.25 mg. CONCLUSION: The use of droperidol or ondansetron for PONV prophylaxis is associated to a low incidence of akathisia (0.8 to 3.4%) after general anaesthesia for ambulatory surgery. TRIAL REGISTRATION: Clinicaltrials.gov: NCT01942343.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Charton A, Greib N, Ruimy A, et al. Incidence of akathisia after postoperative nausea and vomiting prophylaxis with droperidol and ondansetron in outpatient surgery: A multicentre controlled randomised trial. Eur J Anaesthesiol. 2018. PMID: 29746373. doi:10.1097/EJA.0000000000000821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。